Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV003394789 | SCV004129946 | likely pathogenic | not provided | 2022-12-01 | criteria provided, single submitter | clinical testing | FANCF: PVS1:Strong, PM2 |
Baylor Genetics | RCV003459861 | SCV004199108 | likely pathogenic | Fanconi anemia complementation group F | 2022-12-07 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003636016 | SCV004377089 | pathogenic | Fanconi anemia | 2024-01-19 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Gln130Profs*23) in the FANCF gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 245 amino acid(s) of the FANCF protein. This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with FANCF-related conditions. ClinVar contains an entry for this variant (Variation ID: 2641690). This variant disrupts a region of the FANCF protein in which other variant(s) (p.Gly231Glufs*7) have been determined to be pathogenic (PMID: 11063725, 12649160, 27714961). This suggests that this is a clinically significant region of the protein, and that variants that disrupt it are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. |